Abbott Laboratories Corporation

Other

Sushil G. Devare

James M. Casey

Suresh M. Desai

Virender K. Sarin

Ilse I. E. Tribby

Jeffrey C. Hunt

Jill Johnson-paepke

Suresh M Desai

George J Dawson

Thomas P Leary

Anthony Scott Muerhoff

Sushil G Devare

Isa K Mushahwar

John N Simons

Larry G Birkenmeyer

James M Casey

Tami J Pilot-Matias

James Carl Erker

A Scott Muerhoff

Robin A Gutierrez

George G Schlauder

Sheri L Buijk

Dinesh O Shah

James L Stewart

Bruce J Dille

Julie Yamaguchi

Stephen H Dailey

Joan D Tyner

John C Prostko

Richard R Lesniewski

Kevin R Rupprecht

Smriti U Mehta

Lily Jiang

Michelle Chalmers

Ruthie E Coffey

Jill E Johnson

Donald E Frail

Billy J Zeck

Suzanne L Bode

David J Hawksworth

Robert N Ziemann

Bryan C Tieman

Jeffrey C Hunt

Qiaoqiao Ruan

Sergey Y Tetin

Bailin Tu

Frank C Grenier

Ronald L Marshall

Robert William Siegel

Christopher C Marohnic

Ryan F Workman

Virender K Sarin

Robert J Carrick

Larry T Mimms

Edward T Olejniczak

Cynthia Jou

Wlodzimierz Mandecki

M Felicia Bogdan

Timothy J Bolling

Teresa K Surowy

Robin A Guetierrez

Scott Muerhoff

Ilse I Tribby

Yu Cheng

Shinichi Watanabe

Sheela M George

Mary S Gibadlo

Xingli Jiang

George A Dawson

Jill Johnson-Paepke

Ilse I E Tribby

The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.

HCV antigen-antibody combination assay and methods and compositions for use therein

A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.

Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of, and methods of using these polynucleotides and polypeptides in the detection ofantibodies or anti-antibodies in a subject. The invention finds particular useful application in identifying recent exposure to

[object Object]

The present invention relates to one or more peptides which may be used to test for the presence of antibodies to. These peptide are selected based on the strength and specificity of the human antibody response to. These peptides alone or in combination have a variety of uses, for example, as a component of a diagnostic assay or kit.

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesand. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesandSuch genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply.

Methods for the simultaneous detection of HCV antigens and HCV antibodies

Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use

Unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.

Hepatitis C assay utilizing recombinant antigens

Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use

Growing community of inventors

Libertyville, IL, United States of America

Suresh M Desai